+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

US Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

  • ID: 4752285
  • Report
  • February 2019
  • Region: United States
  • 109 pages
  • IMARC Group
1 of 3

FEATURED COMPANIES

  • Actavis
  • Dr Reddy's
  • Endo Pharmaceuticals
  • Hospira
  • Lupin Pharmaceuticals
  • Mylan
  • MORE
The US generic drug market has witnessed a transformation over the last three decades. From less than 20% of the total prescriptions, generic drugs now account for the majority of the total prescriptions dispensed in the United States. During 2011-2018, the US generic drug market grew at a CAGR of 12% and currently represents a multibillion dollar industry. The biggest catalyst of this industry is the significantly lower price of generics compared to branded drugs. Although generics are chemically identical to their branded counterparts, they are typically sold at substantial discounts from the branded price. This has enabled governments and third-party payers to save billions of dollars in healthcare expenditures and resulted in lower copayments for patients. Other factors such as patent expiration of blockbuster innovator drugs, ageing population and an increasing prevalence of chronic diseases have also acted as catalysts for this market.

The report entitled “US Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024” provides a comprehensive insight into the historical and current trends as well as the future prospects of the generic drug market in the United States. This study serves as an exceptional tool to understand the sales trends, volume trends, growth, key segments, competitive structure, regulations, major manufacturer, major distributors, top drugs, manufacturing requirements, opportunities and future prospects of the US generic drug market. This report can serve as an excellent guide for manufacturers, consultants, researchers, marketing strategists and all those who plan to foray into the US generic drug market in any form.

Key Questions Answered in This Report:
  • Historical, current and future sales trends in the US generic drug market?
  • Historical, current and future prescription trends in the US generic drug market?
  • Performance of the US generic drug market compared to the US pharmaceutical market?
  • Performance of the US generic drug market compared to other major generic drug markets?
  • Structure of the US generic drug market?
  • Market Breakup by Therapy Area?
  • Market Breakup by Drug Delivery?
  • Market Breakup by Distribution Channel?
  • Competitive landscape in the US generic drug market?
  • Top US generic drug manufacturers and their market shares?
  • Distribution of generic drugs in the US?
  • Top US generic drug distributors and their market shares?
  • Most prescribed generic drugs in the US?
  • Pricing analysis of generic drugs?
  • Value chain analysis of generic drugs in the US?
  • Regulations in the US generic drug market?
  • Manufacturing process of generic drugs?
  • Machinery and raw material requirements for manufacturing generic drugs?
  • Key success and risk factors in the US generic drug market?
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Actavis
  • Dr Reddy's
  • Endo Pharmaceuticals
  • Hospira
  • Lupin Pharmaceuticals
  • Mylan
  • MORE
1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 US Generic Drug Market - Introduction
4.1 What are Generic Drugs?
4.2 Unbranded and Branded Generics
4.3 Authorized Generics
4.4 Commoditized and Specialty Generics

5 Why is the US Generic Drug Market So Lucrative
5.1 Patent Expiry of Blockbuster Drugs
5.2 Significant Price Differential between Generics and Innovator Drugs
5.3 Savings for the Government and Third-Party Payers
5.4 Incentives for Dispensing and Prescribing Generic Drugs
5.5 Reimbursement and Lower Co-payments
5.6 Biosimilars

6 Global Generic Drug Market
6.1 Market Performance
6.1.1 Volume Trends
6.1.2 Value Trends
6.2 Market Breakup by Country
6.3 Market Forecast
6.4 Most Prescribed Generic and Branded Drugs

7 US Generic Drug Market
7.1 US Pharmaceutical Market Performance
7.1.1 Volume Trends
7.1.2 Value Trends
7.1.3 Market Breakup by Type
7.1.4 Market Forecast
7.2 US Generic Drug Market Performance
7.2.1 Volume Trends
7.2.2 Value Trends
7.2.3 Market Breakup by Segment
7.2.4 Market Breakup by Therapy Area
7.2.5 Market Breakup by Drug Delivery
7.2.6 Market Breakup by Distribution Channel
7.2.7 Market Forecast

8 Market Breakup by Segment
8.1 Unbranded Generics
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Branded Generics
8.2.1 Market Trends
8.2.2 Market Forecast

9 Market Breakup by Therapy Area
9.1 CNS
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Cardiovascular
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Dermatology
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Genitourinary/Hormonal
9.4.1 Market Trends
9.4.2 Market Forecast
9.5 Respiratory
9.5.1 Market Trends
9.5.2 Market Forecast
9.6 Rheumatology
9.6.1 Market Trends
9.6.2 Market Forecast
9.7 Diabetes
9.7.1 Market Trends
9.7.2 Market Forecast
9.8 Oncology
9.8.1 Market Trends
9.8.2 Market Forecast
9.9 Others
9.9.1 Market Trends
9.9.2 Market Forecast

10 Market Breakup by Drug Delivery
10.1 Oral
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Injectables
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Dermal/Topical
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Inhalers
10.4.1 Market Trends
10.4.2 Market Forecast

11 Market Breakup by Distribution Channel
11.1 Retail Pharmacies
11.1.1 Market Trends
11.1.2 Market Forecast
11.2 Hospital Pharmacies
11.2.1 Market Trends
11.2.2 Market Forecast

12 US Generic Drug Market - SWOT Analysis
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats

13 US Generic Drug Market - Value Chain Analysis
13.1 Research and Development
13.2 Raw Material Procurement
13.3 Manufacturing
13.4 Marketing
13.5 Distribution

14 Pricing Mechanism and Profit Margins at Various Levels of the Supply Chain

15 Porter’s Five Forces Analysis
15.1 Overview
15.2 Bargaining Power of Buyers
15.3 Bargaining Power of Suppliers
15.4 Degree of Rivalry
15.5 Threat of New Entrants
15.6 Threat of Substitutes

16 US Generic Drug Market- Competitive Landscape
16.1 US Generic Drug Market - Competitive Structure
16.2 US Generic Drug Market - Breakup of Key Players
16.4 US Generic Drug Market - Most Prescribed Generic Drugs
16.5 US Generic Drug Market - Market Breakup by Distribution
16.6 US Generic Drug Market - Pricing Dynamics

17 Regulations in the US Generic Drug Industry
17.1 Overview of Pharmaceutical Regulations
17.2 Drug Applications
17.3 Patents and Market Exclusivity
17.4 Regulatory Requirements for Generic Drugs
17.5 The Hatch-Waxman Act
17.6 Certifications
17.7 Other Important Considerations

18 US Generic Drug Market: Key Success Factors

19 US Generic Drug Market: Road Blocks

20 Requirements for Setting Up a Generic Drug Manufacturing Plant
20.1 Manufacturing Process
20.2 Raw Material Requirements
20.3 Raw Materials Pictures
20.4 Land and Construction Requirements
20.5 Machinery and Infrastructure Requirements
20.6 Machinery Pictures
20.7 Plant Layout
20.8 Packaging Requirements
20.9 Utility Requirements
20.10 Manpower Requirements

21 US Generic Drug Market - Key Company Profiles
21.1 Teva
21.2 Mylan
21.3 Actavis
21.4 Sandoz
21.5 Sun Pharma
21.6 Par Pharmaceuticals
21.7 Endo Pharmaceuticals
21.8 Lupin Pharmaceuticals
21.9 Dr Reddy’s
21.10 Hospira
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Teva
  • Mylan
  • Actavis
  • Sandoz
  • Sun Pharma
  • Par Pharmaceuticals
  • Endo Pharmaceuticals
  • Lupin Pharmaceuticals
  • Dr Reddy's
  • Hospira
Note: Product cover images may vary from those shown
Adroll
adroll